BMC Public Health 2006, 6:3 Additional material Additional File 1 Questionnaire-For questionnaire used in the national survey. Click here for file [http://www.biomedcentral.com/content/supplementary/1471- 2458-6-3-S1.doc] Acknowledgements We thank all those who took part in the national survey, and the members of the steering group for their helpful advice and support: (Steve Ryder, John Dillon, Christopher Tibbs). References 1. World Health Organisation: Hepatitis C -global prevalence - update. Wkly epidemiol rec 2002, 77:41-8. 2. Marcellin P, Asselah T, Boyer N: Fibrosis and disease progression in hepatitis C. Hepatology 2002, 36:S47-S56. 3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Rein- dollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginter- feron alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-65. 4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. N Engl J Med 2002, 347:975-82. 5. National Institute for Clinical Excellence: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treat- ment of chronic Hepatitis C. TA75. London 2004. 6. Scottish Medicines Consortium: Pegylated interferon 2a and Hepatitis C in adults. 2002. 7. Department of Health E&W: Hepatitis C strategy for England. London 2002. 8. Department of Health E&W: Hepatitis C Action Plan for Eng- land. 2004. 9. Scottish Needs Assessment Programme Office for Public Health in Scotland: Hepatitis C. Glasgow 2000. 10. Cohen S: Managed Public Health Networks Turning theory into practice. [http://www.fph.org.uk/policy%5Fcommunication/ publications/]. 11. British Liver Trust website [http://www.britishlivertrust.org.uk] 12. EASL International Consensus Conference on Hepatitis C: Consen- sus Statement on Hepatitis C. Journal of Hepatology 1999, 30:956-961. 13. National Institute of Health Consensus Development Program: Man- agement of Hepatitis C. 2002. 14. Strader DB, Wright T, Thomas DL, Seef LB: Diagnosis, Manage- ment, and Treatment of Hepatitis C. Hepatology 2004, 39(4):1147-1171. 15. Scottish Centre for Infection and Environmental Health: [http:// www.show.scot.nhs.uk/scieh]. 16. Health Protection Agency England & Wales: [http://www.hpa.org.uk/ infections]. 17. The British Liver Trust: Hepatitis C – The Public Stealth Dis- ease. 2002. 18. Department of Health E&W: Getting Ahead of the Curve A strategy for combating infectious diseases. London 2002. 19. Bird SM, Goldberg DJ, Hutchinson SJ: Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Journal of Epidemiol & Biostatistics 2001, 6:267-77. 20. Law MG, Dore GJ, Bath N, Thompson S, Crofts N, Dolan K, Giles W, Gow P, Kaldor J, Loveday S, Powell E, Spencer J, Wodak A: Model- ling hepatitis c virus incidence, prevalence and long-term sequelae in Australia, 2001. International Journal of Epidemiology 2001, 32:717-24. 21. Zou S, Tepper M, El Saadany S: Prediction of hepatitis C burden in Canada. Can J Gastroenterol 2000, 14(7):575-580. http://www.biomedcentral.com/1471-2458/6/3 22. Buti M, San Miguel R, Brosa M, Cabases JM, Medina M, Casado MA, Fosbrook L, Esteban R: Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005, 42:639-645. 23. Parkes J, Roderick P, Bennett LLoyd B, Rosenberg WM: Hepatitis C in the United Kingdom. A review of prevalence and service delivery. British Association for the Study of the Liver 2003. 24. Hutchinson SJ, McIntyre PG, Molyneaux P, Cameron S, Burns S, Tay- lor A, Goldberg DJ: Prevalence of hepatitis C among injectors in Scotland 1989–2000: declining trends among young injec- tors halt in the late 1990s. Epidemiol & Infect 2002, 128:473-7. 25. Hope V, Judd A, Hickman M, Lamagni T, Hunter G, Stimson G, Jones S, Donovan L, Parry J, Gill N: Prevalence of Hepatitis C Among Injection Drug Users in England and Wales: Is Harm Reduc- tion Working? Am J Public Health 2001, 91:38-42. 26. Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM: Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut 2003, 52:1500-4. 27. Gore SM, Bird AC, Cameron SO, Hutchinson SJ, Burns SM, Goldberg DJ: Prevalence of hepatitis C in prisons: WASH-C surveil- lance linked to self-reported risk behaviours. QJM 1999, 92:25-32. 28. Weild AR, Gill ON, Bennett D, Livingstone SJM, Parry JV, Curran L: Prevalence of HIV, hepatitis B and hepatitis C antibodies in prisoners in England and Wales: a national survey. Commun Dis Public Health 2000, 3:121-6. 29. Champion JK, Taylor A, Hutchinson S, Cameron S, McMenamin J, Mitchell A, Goldberg D: Incidence of hepatitis C virus infection and associated risk factors among Scottish prison inmates: a cohort study. Am J Epidemiol 2004, 159:514-9. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2458/6/3/prepub Publish with Bio Med Central and every scientist can read your work free of charge "BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime." Sir Paul Nurse, Cancer Research UK Your research papers will be: available free of charge to the entire biomedical community peer reviewed and published immediately upon acceptance cited in PubMed and archived on PubMed Central yours — you keep the copyright Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp BioMedcentral Page 9 of 9 (page number not for citation purposes)